Astrazeneca annual revenue
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Astrazeneca Revenue Growth & History (AZN)
Astrazeneca reported $58.74B in revenue for fiscal 2025, an increase of 8.63% from the previous fiscal year.
View full Astrazeneca company overviewAstrazeneca annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $58.74B | $4.67B | +8.63% |
| 2024 | 2024-12-31 | $54.07B | $8.26B | +18.03% |
| 2023 | 2023-12-31 | $45.81B | $1.46B | +3.29% |
| 2022 | 2022-12-31 | $44.35B | $6.93B | +18.53% |
| 2021 | 2021-12-31 | $37.42B | $10.80B | +40.58% |
| 2020 | 2020-12-31 | $26.62B | $2.23B | +9.16% |
| 2019 | 2019-12-31 | $24.38B | $2.29B | +10.38% |
| 2018 | 2018-12-31 | $22.09B | −$375.0M | −1.67% |
| 2017 | 2017-12-31 | $22.46B | −$537.0M | −2.33% |
| 2016 | 2016-12-31 | $23.00B | −$1.71B | −6.90% |
| 2015 | 2015-12-31 | $24.71B | — | — |
Astrazeneca quarterly revenue
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q2.22
Q2.23
Q2.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $15.38B | $927.0M | +6.41% |
| Q1 2026 | 2026-03-31 | $15.29B | — | — |
| Q4 2025 | 2025-12-31 | $15.50B | — | — |
| Q3 2025 | 2025-09-30 | $15.19B | — | — |
| Q2 2025 | 2025-06-30 | $14.46B | $1.52B | +11.74% |
| Q2 2024 | 2024-06-30 | $12.94B | $1.52B | +13.33% |
| Q2 2023 | 2023-06-30 | $11.42B | $645.0M | +5.99% |
| Q2 2022 | 2022-06-30 | $10.77B | $2.55B | +31.03% |
| Q2 2021 | 2021-06-30 | $8.22B | $1.95B | +31.00% |
| Q1 2021 | 2021-03-31 | $7.26B | $946.0M | +14.99% |
| Q4 2020 | 2020-12-31 | $7.01B | $761.0M | +12.18% |
| Q3 2020 | 2020-09-30 | $6.52B | $388.0M | +6.33% |
| Q2 2020 | 2020-06-30 | $6.28B | $452.0M | +7.76% |
| Q1 2020 | 2020-03-31 | $6.31B | $846.0M | +15.48% |
| Q4 2019 | 2019-12-31 | $6.25B | $482.0M | +8.36% |
| Q3 2019 | 2019-09-30 | $6.13B | $866.0M | +16.45% |
| Q2 2019 | 2019-06-30 | $5.82B | $668.0M | +12.96% |
| Q1 2019 | 2019-03-31 | $5.46B | $480.0M | +9.63% |
| Q4 2018 | 2018-12-31 | $5.77B | $281.0M | +5.12% |
| Q3 2018 | 2018-09-30 | $5.27B | $384.0M | +7.87% |
| Q2 2018 | 2018-06-30 | $5.16B | $104.0M | +2.06% |
| Q1 2018 | 2018-03-31 | $4.99B | $142.0M | +2.93% |
| Q4 2017 | 2017-12-31 | $5.49B | $227.0M | +4.32% |
| Q3 2017 | 2017-09-30 | $4.88B | −$143.0M | −2.85% |
| Q2 2017 | 2017-06-30 | $5.05B | −$418.0M | −7.64% |
| Q1 2017 | 2017-03-31 | $4.84B | −$722.0M | −12.97% |
| Q4 2016 | 2016-12-31 | $5.26B | — | — |
| Q3 2016 | 2016-09-30 | $5.03B | — | — |
| Q2 2016 | 2016-06-30 | $5.47B | — | — |
| Q1 2016 | 2016-03-31 | $5.57B | — | — |
Astrazeneca revenue growth trends
Over the last five reported fiscal years, revenue grew from $26.62B to $58.74B, a compound annual growth rate of 17.15%. Astrazeneca's latest reported quarter, Q2 2026, generated $15.38B in revenue, an increase of 6.41% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Astrazeneca source filings ↗Community posts
AstraZeneca receives priority review for perioperative bladder-cancer regimen
The FDA granted priority review to a regimen combining AstraZeneca ($AZN)’s Imfinzi with enfortumab vedotin around surgery for muscle-invasive bladder cancer in patients ineligible for, or declining, cisplatin chemotherapy. Imfinzi is given ...
AstraZeneca’s Klygefa receives a positive EU recommendation
European medicines advisers recommended AstraZeneca ($AZN)’s Klygefa, or gefurulimab, as an add-on to standard treatment for adults with generalized myasthenia gravis who are positive for anti-acetylcholine receptor antibodies. The Alexion ...
Enhertu receives European recommendation for an earlier breast-cancer setting
European advisers recommended Enhertu for postoperative treatment of adults with HER2-positive breast cancer who still have invasive disease after preoperative taxane-based chemotherapy and HER2-directed treatment. The drug is jointly devel ...
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...
